Innovative science for life-changing medicines
News
Samus Therapeutics Announces First Patient Dosed in Phase 1b Study of Icapamespib in Recurrent Malignant Glioma
January 5, 2022
Download PDF
Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells
December 1, 2021
Download PDF
Samus Therapeutics Announces Publication of Study on Epichaperome Chemical Probes in Nature Communications
September 2, 2021
Download PDF
Samus Therapeutics Receives IND Clearance from FDA for PU-AD for the Treatment of Recurrent Malignant Glioma
May 11, 2021
Download PDF
Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company’s Platform for Treating Neurodegenerative Diseases
July 29, 2020
Download PDF
Samus Therapeutics to Present at BIO CEO & Investor Conference
February 4, 2020
Download PDF
Study Published in Nature Communications Highlights the Role of the Epichaperome in Protein Connectivity-based Dysfunction in Alzheimer’s Disease
February 4, 2020
Download PDF
Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting
December 9, 2019
Download PDF
Samus Therapeutics Announces Presentation of PU-AD Phase 1 Data for Alzheimer’s Disease at CTAD Congress
December 5, 2019
Download PDF
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer’s Disease
July 23, 2019
Download PDF
Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis
June 13, 2018
Download PDF
Samus Therapeutics Announces Launch of Expanded Clinical Development Programs for Novel Anti-Epichaperome Small Molecules to Diagnose and Treat Cancer and Neurodegenerative Disease
March 30, 2017
Download PDF
